{"id":"NCT01040689","sponsor":"Boehringer Ingelheim","briefTitle":"Characterization of 24 Hour Spirometry Profiles of Inhaled BI 1744 CL and Inhaled Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease","officialTitle":"Randomised, Double-blind, Double-dummy, Placebo-controlled, 4-way Cross-over Study to Characterise the 24-hour Forced, Expiratory Volume After 1 Second (FEV1) Time Profiles of BI 1744 CL 5µg and 10µg (Oral Inhalation, Delivered by the Respimat® Inhaler) and Tiotropium Bromide 18µg (Oral Inhalation, Delivered by the HandiHaler®) After 6 Weeks of Treatment in Patients With Chronic Obstructive Pulmonary Disease (COPD)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-01","primaryCompletion":"2011-01","completion":null,"firstPosted":"2009-12-30","resultsPosted":"2014-06-30","lastUpdate":"2014-06-30"},"enrollment":108,"design":{"allocation":"RANDOMIZED","model":"CROSSOVER","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Disease, Chronic Obstructive"],"interventions":[{"type":"DRUG","name":"Olodaterol (BI1744) Low","otherNames":[]},{"type":"DRUG","name":"Placebo (for olodaterol BI1744)","otherNames":[]},{"type":"DRUG","name":"Placebo (for Tiotropium)","otherNames":[]},{"type":"DRUG","name":"Olodaterol (BI1744) High","otherNames":[]},{"type":"DRUG","name":"Tiotropium 18 mcg","otherNames":[]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Olodaterol (BI1744) Low","type":"EXPERIMENTAL"},{"label":"Olodaterol (BI1744) High","type":"EXPERIMENTAL"},{"label":"Tiotropium 18 mcg","type":"ACTIVE_COMPARATOR"}],"summary":"The study is intended to characterize the lung function profile of BI1744 in COPD patients where patients will perform pulmonary function tests at regular intervals for 24 hours at the end of a 6 week treatment period. Each patient will receive all four treatments.","primaryOutcome":{"measure":"FEV1 Area Under Curve 0-12 h (AUC 0-12h) Response After Six Weeks of Treatment","timeFrame":"1 hour (h) and 10 minutes (min) prior to am dose on the first day of the first treatment period (study baseline) and -30 min (zero time), 30 min, 60 min, 2 hour (h) , 3 h, 4 h, 6 h, 8 h, 10 h, 12 h relative to am dose after six weeks of treatment","effectByArm":[{"arm":"Placebo","deltaMin":-0.054,"sd":0.02},{"arm":"Olo 5 mcg qd","deltaMin":0.131,"sd":0.02},{"arm":"Olo 10 mcg qd","deltaMin":0.152,"sd":0.02},{"arm":"Tio 18 mcg qd","deltaMin":0.119,"sd":0.02}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"},{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG000 vs OG003","p":"<0.0001"}]},"eligibility":{"minAge":"40 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":16},"locations":{"siteCount":15,"countries":["Belgium","Denmark","Germany","Hungary"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":5,"n":102},"commonTop":["Nasopharyngitis","Chronic obstructive pulmonary disease"]}}